Home › Treatment-Resistant Depressive Disorder › NCT05905705

Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

Who can join

Ages 21 to 65 · All sexes

Inclusion Criteria:

* Referral for initial ECT index course for Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression. Historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for TRD diagnostic.

Exclusion Criteria:

* Diagnoses of schizophrenia or schizoaffective disorders.
* Subjects who are unable to tolerate the Dreem device for sleep recordings will be excluded from the study.

About the study

Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

What is being tested

• Electroencephalography (EEG) (diagnostic test)
• Quantitative Measurements of Sleep Microstructure (diagnostic test)

Sponsor: Washington University School of Medicine · Participants: 50 · Started: Mar 7, 2023

Contact the study team

• Robby Greenspan · Phone: 314-273-6129
• MohammadMehdi Kafashan · Phone: 314-273-8848

Official record on ClinicalTrials.gov — NCT05905705

Locations in the U.S.

Conditions

• Treatment-Resistant Depressive Disorder

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.